Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 67

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections

Guo, Yutong, Mao, Zeyuan, Ran, Fang, Sun, Jihong, Zhang, Jingfeng, Chai, Guihong, Wang, Jian·2023·Pharmaceutics

Abstract

Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in clinical settings due to their increased tolerance to currently available antibiotics and host immune responses, resulting in chronic infections with high recalcitrance and high rates of morbidity and mortality. To address these unmet clinical needs, potential anti-biofilm therapeutic strategies are being developed to effectively control bacterial biofilm. This review focuses on recent advances in the development and application of nanoparticulate drug delivery systems for the treatment of biofilm-associated respiratory tract infections, especially addressing the respiratory barriers of concern for biofilm accessibility and the various types of nanoparticles used to combat biofilms. Understanding the obstacles facing pulmonary drug delivery to bacterial biofilms and nanoparticle-based approaches to combatting biofilm may encourage researchers to explore promising treatment modalities for bacterial-biofilm-associated chronic lung infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15112582

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 252

  1. Azoulay, 2020, Diagnosis of severe respiratory infections in immunocompromised patients, Intensive Care Med., 46, 298, 10.1007/s00134-019-05906-5 · DOI · Paper page
  2. Hutchinson, 2018, Influenza Virus, Trends Microbiol., 26, 809, 10.1016/j.tim.2018.05.013 · DOI
  3. Langedijk, 2023, Respiratory syncytial virus infection and novel interventions, Nat. Rev. Microbiol., 21, 734, 10.1038/s41579-023-00919-w · DOI · Paper page
  4. Borczuk, A.C., and Yantiss, R.K. (2022). The pathogenesis of coronavirus-19 disease. J. Biomed. Sci., 29. · DOI
  5. Rostami, A., Liu, M.-C., Xu, Q., Li, T.-T., Wang, T., Jiang, B.-G., Lv, C.-L., Zhang, X.-A., Liu, W., and Fang, L.-Q. (2023). Prevalence of human infection with respiratory adenovirus in China: A systematic review and meta-analysis. PLoS Neglected Trop. Dis., 17. · DOI
  6. Shang, 2020, Viral pneumonia in China: From surveillance to response, Lancet Public. Health, 5, e633, 10.1016/S2468-2667(20)30264-4 · doi:10.1016/s2468-2667(20)30264-4
  7. Cone, 2009, Barrier properties of mucus, Adv. Drug Deliv. Rev., 61, 75, 10.1016/j.addr.2008.09.008 · DOI · Paper page
  8. Vanaki, S.M., Holmes, D., Saha, S.C., Chen, J., Brown, R.J., and Jayathilake, P.G. (2020). Muco-ciliary clearance: A review of modelling techniques. J. Biomech., 99. · DOI
  9. Fahy, 2010, Airway mucus function and dysfunction, N. Engl. J. Med., 363, 2233, 10.1056/NEJMra0910061 · DOI · Paper page
  10. Ding, 2021, Pulmonary biofilm-based chronic infections and inhaled treatment strategies, Int. J. Pharm., 604, 120768, 10.1016/j.ijpharm.2021.120768 · DOI
  11. Ciofu, 2015, Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients, Adv. Drug Deliv. Rev., 85, 7, 10.1016/j.addr.2014.11.017 · DOI · Paper page
  12. Potera, 1999, Microbiology—Forging a link between biofilms and disease, Science, 283, 1837, 10.1126/science.283.5409.1837 · DOI · Paper page
  13. Costerton, 1999, Bacterial biofilms: A common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
  14. Ciofu, 2022, Tolerance and resistance of microbial biofilms, Nat. Rev. Microbiol., 20, 621, 10.1038/s41579-022-00682-4 · DOI · Paper page
  15. Sharma, 2021, Advances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases, Nanomedicine, 16, 1905, 10.2217/nnm-2021-0057 · DOI
  16. Zhang, 2022, Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections, Int. J. Pharm., 616, 121507, 10.1016/j.ijpharm.2022.121507 · DOI
  17. Selmani, 2022, Nanoparticles: From synthesis to applications and beyond, Adv. Colloid. Interface Sci., 303, 102640, 10.1016/j.cis.2022.102640 · DOI · Paper page
  18. Wu, 2018, Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties, Adv. Drug Deliv. Rev., 124, 150, 10.1016/j.addr.2017.10.001 · DOI · Paper page
  19. Murgia, 2018, The role of mucus on drug transport and its potential to affect therapeutic outcomes, Adv. Drug Deliv. Rev., 124, 82, 10.1016/j.addr.2017.10.009 · DOI · Paper page
  20. Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm., 532, 555, 10.1016/j.ijpharm.2017.09.018 · DOI · Paper page
  21. Button, 2012, A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia, Science, 337, 937, 10.1126/science.1223012 · DOI · Paper page
  22. Sears, 2011, Mucociliary interactions and mucus dynamics in ciliated human bronchial epithelial cell cultures, Am. J. Physiol. Lung Cell Mol. Physiol., 301, L181, 10.1152/ajplung.00321.2010 · DOI
  23. Liu, 2015, Developments of mucus penetrating nanoparticles, Asian J. Pharm. Sci., 10, 275, 10.1016/j.ajps.2014.12.007 · DOI · Paper page
  24. Song, 2021, Modeling Airway Dysfunction in Asthma Using Synthetic Mucus Biomaterials, ACS Biomater. Sci. Eng., 7, 2723, 10.1021/acsbiomaterials.0c01728 · DOI
  25. Patarin, 2020, Rheological analysis of sputum from patients with chronic bronchial diseases, Sci. Rep., 10, 15685, 10.1038/s41598-020-72672-6 · doi:10.1038/s41598-020-72672-6
  26. Duncan, 2016, Microstructural alterations of sputum in cystic fibrosis lung disease, JCI Insight, 1, e88198, 10.1172/jci.insight.88198 · DOI
  27. Linssen, 2021, Neutrophil Extracellular Traps Increase Airway Mucus Viscoelasticity and Slow Mucus Particle Transit, Am. J. Respir. Cell Mol. Biol., 64, 69, 10.1165/rcmb.2020-0168OC · DOI
  28. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
  29. Schneider, 2017, Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation, Sci. Adv., 3, e1601556, 10.1126/sciadv.1601556 · DOI · Paper page
  30. Xu, 2015, Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo, ACS Nano, 9, 9217, 10.1021/acsnano.5b03876 · DOI · Paper page
  31. Seiler, 2014, Regulation and function of antimicrobial peptides in immunity and diseases of the lung, Protein Pept. Lett., 21, 341, 10.2174/09298665113206660100 · doi:10.2174/09298665113206660100
  32. Lecaille, 2016, Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases, Biochimie, 122, 151, 10.1016/j.biochi.2015.08.014 · DOI
  33. James, 2008, Biofilms in chronic wounds, Wound Repair. Regen., 16, 37, 10.1111/j.1524-475X.2007.00321.x · DOI · Paper page
  34. Haesler, 2019, Clinical indicators of wound infection and biofilm: Reaching international consensus, J. Wound Care, 28, s4, 10.12968/jowc.2019.28.Sup3b.S4 · DOI
  35. Xie, 2022, Cholesterol Microdomain Enhances the Biofilm Eradication of Antibiotic Liposomes, Adv. Healthc. Mater., 11, 2101745, 10.1002/adhm.202101745 · DOI
  36. Jean-Pierre, V., Boudet, A., Sorlin, P., Menetrey, Q., Chiron, R., Lavigne, J.-P., and Marchandin, H. (2022). Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis. Int. J. Mol. Sci., 24. · DOI
  37. Weiser, 2018, Streptococcus pneumoniae: Transmission, colonization and invasion, Nat. Rev. Microbiol., 16, 355, 10.1038/s41579-018-0001-8 · DOI · Paper page
  38. Margalit, 2020, Clinical correlates of nocardiosis, Sci. Rep., 10, 14272, 10.1038/s41598-020-71214-4 · DOI
  39. Xiu, 2023, Ultrasound-responsive catalytic microbubbles enhance biofilm elimination and immune activation to treat chronic lung infections, Sci. Adv., 9, eade5446, 10.1126/sciadv.ade5446 · DOI
  40. Bajire, S.K., Prabhu, A., Bhandary, Y.P., Irfan, K.M., and Shastry, R.P. (2023). 7-Ethoxycoumarin rescued Caenorhabditis elegans from infection of COPD derived clinical isolate Pseudomonas aeruginosa through virulence and biofilm inhibition via targeting Rhl and Pqs quorum sensing systems. World J. Microbiol. Biotechnol., 39. · DOI
  41. Ricard, 2018, Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence, Int. J. Med. Microbiol., 308, 290, 10.1016/j.ijmm.2018.01.003 · DOI
  42. Kharga, K., Dhar, I., Kashyap, S., Sengupta, S., Kumar, D., and Kumar, L. (2023). Zingerone inhibits biofilm formation and enhances antibiotic efficacy against Salmonella biofilm. World J. Microbiol. Biotechnol., 39. · DOI
  43. Li, Y., and Ni, M. (2023). Regulation of biofilm formation in Klebsiella pneumoniae. Front. Microbiol., 14. · DOI
  44. Marienborg, 2023, The alginate polymer OligoG alters susceptibility of biofilm-embedded non-typeable Haemophilus influenzae to ampicillin and ciprofloxacin, JAC-Antimicrob. Resist., 5, dlad046, 10.1093/jacamr/dlad046 · doi:10.1093/jacamr/dlad046
  45. Earle, 2023, Pathogenicity and virulence of Aspergillus fumigatus, Virulence, 14, 2172264, 10.1080/21505594.2023.2172264 · DOI
  46. Bouyssi, A., Déméautis, T., Trecourt, A., Delles, M., Agostini, F., Monneret, G., Glehen, O., Wallon, M., Persat, F., and Devouassoux, G. (2023). Characterization of Lung Inflammatory Response to Aspergillus fumigatus Spores. J. Fungi, 9. · DOI
  47. Linder, K.A., Kauffman, C.A., and Miceli, M.H. (2023). Blastomycosis: A Review of Mycological and Clinical Aspects. J. Fungi, 9. · DOI
  48. Rather, M.A., Saha, D., Bhuyan, S., Jha, A.N., and Mandal, M. (2022). Quorum Quenching: A Drug Discovery Approach Against Pseudomonas aeruginosa. Microbiol. Res., 264. · doi:10.1016/j.micres.2022.127173
  49. Hansen, 2008, Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience, J. Cyst. Fibros., 7, 523, 10.1016/j.jcf.2008.06.009 · DOI
  50. Rumbaugh, 2020, Biofilm dispersion, Nat. Rev. Microbiol., 18, 571, 10.1038/s41579-020-0385-0 · DOI · Paper page
  51. Arora, 2015, Nitric Oxide Regulation of Bacterial Biofilms, Biochemistry, 54, 3717, 10.1021/bi501476n · DOI · Paper page
  52. Bansil, 2018, The biology of mucus: Composition, synthesis and organization, Adv. Drug Deliv. Rev., 124, 3, 10.1016/j.addr.2017.09.023 · DOI · Paper page
  53. Curran, 2018, Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection, Am. J. Respir. Crit. Care Med., 197, 708, 10.1164/rccm.201705-1043SO · DOI · Paper page
  54. Proft, 2009, Pili in Gram-negative and Gram-positive bacteria—Structure, assembly and their role in disease, Cell Mol. Life Sci., 66, 613, 10.1007/s00018-008-8477-4 · DOI · Paper page
  55. Whiteley, 2017, Progress in and promise of bacterial quorum sensing research, Nature, 551, 313, 10.1038/nature24624 · DOI · Paper page
  56. Koo, 2017, Targeting microbial biofilms: Current and prospective therapeutic strategies, Nat. Rev. Microbiol., 15, 740, 10.1038/nrmicro.2017.99 · DOI · Paper page
  57. Yang, 2011, Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development, Environ. Microbiol., 13, 1705, 10.1111/j.1462-2920.2011.02503.x · DOI · Paper page
  58. Giltner, 2005, DNA binding: A novel function of Pseudomonas aeruginosa type IV pili, J. Bacteriol., 187, 1455, 10.1128/JB.187.4.1455-1464.2005 · DOI · Paper page
  59. Yang, 2009, Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation, Mol. Microbiol., 74, 1380, 10.1111/j.1365-2958.2009.06934.x · DOI · Paper page
  60. Bjarnsholt, 2013, Applying insights from biofilm biology to drug development—Can a new approach be developed?, Nat. Rev. Drug Discov., 12, 791, 10.1038/nrd4000 · DOI · Paper page
  61. Klausen, 2003, Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants, Mol. Microbiol., 48, 1511, 10.1046/j.1365-2958.2003.03525.x · DOI · Paper page
  62. Costerton, 2005, Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid Pseudomonas aeruginosa biofilms, Microbiology, 151, 1569, 10.1099/mic.0.27536-0 · DOI · Paper page
  63. Flemming, 2010, The biofilm matrix, Nat. Rev. Microbiol., 8, 623, 10.1038/nrmicro2415 · DOI · Paper page
  64. Byrd, 2009, Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production, Mol. Microbiol., 73, 622, 10.1111/j.1365-2958.2009.06795.x · DOI · Paper page
  65. Mann, 2012, Pseudomonas biofilm matrix composition and niche biology, FEMS Microbiol. Rev., 36, 893, 10.1111/j.1574-6976.2011.00322.x · DOI · Paper page
  66. Ma, 2012, The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms, FEMS Immunol. Med. Microbiol., 65, 377, 10.1111/j.1574-695X.2012.00934.x · DOI
  67. Ma, L., Conover, M., Lu, H., Parsek, M.R., Bayles, K., and Wozniak, D.J. (2009). Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog., 5. · DOI · Paper page
  68. Colvin, K.M., Gordon, V.D., Murakami, K., Borlee, B.R., Wozniak, D.J., Wong, G.C.L., and Parsek, M.R. (2011). The Pel Polysaccharide Can Serve a Structural and Protective Role in the Biofilm Matrix of Pseudomonas aeruginosa. PLoS Pathog., 7. · DOI · Paper page
  69. Jennings, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc. Natl. Acad. Sci. USA, 112, 11353, 10.1073/pnas.1503058112 · DOI · Paper page
  70. Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat. Rev. Microbiol., 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
  71. Maurice, 2018, Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections, Am. J. Respir. Cell Mol. Biol., 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
  72. Hoiby, 2017, Diagnosis of biofilm infections in cystic fibrosis patients, APMIS, 125, 339, 10.1111/apm.12689 · DOI
  73. Paetzold, 2020, Characterization of different alginate lyases for dissolving Pseudomonas aeruginosa biofilms, Sci. Rep., 10, 9390, 10.1038/s41598-020-66293-2 · DOI
  74. Wan, 2020, Alginate Lyase Guided Silver Nanocomposites for Eradicating Pseudomonas aeruginosa from Lungs, ACS Appl. Mater. Interfaces, 12, 9050, 10.1021/acsami.9b21815 · DOI
  75. Powell, L.C., Pritchard, M.F., Ferguson, E.L., Powell, K.A., Patel, S.U., Rye, P.D., Sakellakou, S.M., Buurma, N.J., Brilliant, C.D., and Copping, J.M. (2018). Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides. NPJ Biofilms Microbiomes, 4. · DOI · Paper page
  76. Cendra, M.D., and Torrents, E. (2021). Pseudomonas aeruginosa biofilms and their partners in crime. Biotechnol. Adv., 49. · DOI · Paper page
  77. Sarkar, 2020, Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA, Appl. Microbiol. Biotechnol., 104, 6549, 10.1007/s00253-020-10687-9 · DOI
  78. Das, T., and Manefield, M. (2012). Pyocyanin promotes extracellular DNA release in Pseudomonas aeruginosa. PLoS ONE, 7. · DOI · Paper page
  79. Mulcahy, H., Charron-Mazenod, L., and Lewenza, S. (2008). Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog., 4. · DOI · Paper page
  80. Wang, 2015, The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa, Environ. Microbiol. Rep., 7, 330, 10.1111/1758-2229.12252 · DOI · Paper page
  81. Saunders, 2020, Extracellular DNA Promotes Efficient Extracellular Electron Transfer by Pyocyanin in Pseudomonas aeruginosa Biofilms, Cell, 182, 919, 10.1016/j.cell.2020.07.006 · DOI · Paper page
  82. Chiang, 2013, Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob. Agents Chemother., 57, 2352, 10.1128/AAC.00001-13 · DOI · Paper page
  83. Russo, 2010, Extracellular DNA: A major proinflammatory component of Pseudomonas aeruginosa biofilms, J. Immunol., 184, 6386, 10.4049/jimmunol.0901640 · DOI
  84. Caiazza, 2005, Rhamnolipids modulate swarming motility patterns of Pseudomonas aeruginosa, J. Bacteriol., 187, 7351, 10.1128/JB.187.21.7351-7361.2005 · DOI · Paper page
  85. Zheng, 2017, Synthetic analogs of rhamnolipids modulate structured biofilms formed by rhamnolipid-nonproducing mutant of Pseudomonas aeruginosa, Bioorg. Med. Chem., 25, 1830, 10.1016/j.bmc.2017.01.042 · doi:10.1016/j.bmc.2017.01.042
  86. Wang, 2013, Rhamnolipid but not motility is associated with the initiation of biofilm seeding dispersal of Pseudomonas aeruginosa strain PA17, J. Biosci., 38, 149, 10.1007/s12038-012-9297-0 · DOI
  87. Domingue, 2020, Host responses to mucosal biofilms in the lung and gut, Mucosal Immunol., 13, 413, 10.1038/s41385-020-0270-1 · DOI
  88. Hoiby, 2010, Pseudomonas aeruginosa biofilms in cystic fibrosis, Future Microbiol., 5, 1663, 10.2217/fmb.10.125 · DOI · Paper page
  89. Parks, 2009, Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: Human F-actin and DNA as targets for therapy, J. Med. Microbiol., 58, 492, 10.1099/jmm.0.005728-0 · DOI
  90. Pedraz, 2020, Gradual adaptation of facultative anaerobic pathogens to microaerobic and anaerobic conditions, FASEB J., 34, 2912, 10.1096/fj.201902861R · DOI
  91. Kamath, 2017, Pseudomonas aeruginosa Proteome under Hypoxic Stress Conditions Mimicking the Cystic Fibrosis Lung, J. Proteome Res., 16, 3917, 10.1021/acs.jproteome.7b00561 · DOI
  92. Zhao, 2018, Oxygen effects on rhamnolipids production by Pseudomonas aeruginosa, Microb. Cell Fact., 17, 39, 10.1186/s12934-018-0888-9 · DOI
  93. Zhang, 2019, Pseudomonas aeruginosa Regulatory Protein AnvM Controls Pathogenicity in Anaerobic Environments and Impacts Host Defense, mBio, 10, 10, 10.1128/mBio.01362-19 · DOI
  94. Baral, 2020, Strategic Moves of “Superbugs” Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges, ACS Pharmacol. Transl., 3, 373, 10.1021/acsptsci.0c00005 · DOI
  95. Olivares, E., Badel-Berchoux, S., Provot, C., Prevost, G., Bernardi, T., and Jehl, F. (2019). Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections. Front. Microbiol., 10. · DOI · Paper page
  96. Uruen, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R.C., and Arenas, J. (2021). Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics, 10. · DOI · Paper page
  97. Paranjape, 2019, Comparison of Starvation-Induced Persister Cells with Antibiotic-Induced Persister Cells, Curr. Microbiol., 76, 1495, 10.1007/s00284-019-01777-7 · DOI
  98. Moldoveanu, 2021, Impact of bacterial persisters on their host, Curr. Opin. Microbiol., 59, 65, 10.1016/j.mib.2020.07.006 · DOI · Paper page
  99. Chattagul, 2021, Transcriptomics Analysis Uncovers Transient Ceftazidime Tolerance in Burkholderia Biofilms, ACS Infect. Dis., 7, 2324, 10.1021/acsinfecdis.1c00003 · DOI
  100. Poudyal, 2018, The PA3177 Gene Encodes an Active Diguanylate Cyclase That Contributes to Biofilm Antimicrobial Tolerance but Not Biofilm Formation by Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 62, 10, 10.1128/AAC.01049-18 · DOI
  101. Poudyal, 2018, The ABC of Biofilm Drug Tolerance: The MerR-Like Regulator BrlR Is an Activator of ABC Transport Systems, with PA1874-77 Contributing to the Tolerance of Pseudomonas aeruginosa Biofilms to Tobramycin, Antimicrob. Agents Chemother., 62, 10, 10.1128/AAC.01981-17 · DOI
  102. Gao, 2020, Size and Charge Adaptive Clustered Nanoparticles Targeting the Biofilm Microenvironment for Chronic Lung Infection Management, ACS Nano, 14, 5686, 10.1021/acsnano.0c00269 · DOI · Paper page
  103. Yang, 2023, Self-Adaptive Antibiofilm Effect and Immune Regulation by Hollow Cu2MoS4 Nanospheres for Treatment of Implant Infections, ACS Appl. Mater. Interfaces, 15, 18720, 10.1021/acsami.3c01928 · DOI
  104. Hu, 2023, Hybrid Biomimetic Membrane Coated Particles-Mediated Bacterial Ferroptosis for Acute MRSA Pneumonia, ACS Nano, 17, 11692, 10.1021/acsnano.3c02365 · DOI
  105. Zhao, 2019, Bioinspired Heteromultivalent Ligand-Decorated Nanotherapeutic for Enhanced Photothermal and Photodynamic Therapy of Antibiotic-Resistant Bacterial Pneumonia, ACS Appl. Mater. Interfaces, 11, 39648, 10.1021/acsami.9b15118 · DOI
  106. Liu, 2020, Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery, Drug Discov. Today, 25, 150, 10.1016/j.drudis.2019.09.023 · DOI · Paper page
  107. Yue, 2023, Inhaled drug delivery: Past, present, and future, Nano Today, 52, 101942, 10.1016/j.nantod.2023.101942 · DOI
  108. Chen, 2021, Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung, Expert. Opin. Drug Deliv., 18, 595, 10.1080/17425247.2021.1854222 · DOI
  109. Pangeni, 2023, Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers, Int. J. Pharm., 634, 122661, 10.1016/j.ijpharm.2023.122661 · DOI
  110. Zhao, 2022, Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung, Eur. J. Pharm. Biopharm., 172, 101, 10.1016/j.ejpb.2022.01.009 · DOI
  111. Ma, 2023, pH-Mediated Mucus Penetration of Zwitterionic Polydopamine-Modified Silica Nanoparticles, Nano Lett., 23, 7552, 10.1021/acs.nanolett.3c02128 · DOI
  112. Martins, 2018, Chemical modification of drug molecules as strategy to reduce interactions with mucus, Adv. Drug Deliv. Rev., 124, 98, 10.1016/j.addr.2017.09.020 · DOI
  113. Chono, 2008, Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes, J. Drug Target., 14, 557, 10.1080/10611860600834375 · DOI
  114. Seydoux, 2016, Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4(+) T Cell Proliferation, Nanomed-Nanotechnol., 12, 1815, 10.1016/j.nano.2016.02.020 · DOI
  115. Falahati, 2023, Engineering of pulmonary surfactant corona on inhaled nanoparticles to operate in the lung system, Nano Today, 52, 101998, 10.1016/j.nantod.2023.101998 · DOI
  116. Hidalgo, 2019, The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles, Eur. J. Pharm. Biopharm., 144, 230, 10.1016/j.ejpb.2019.09.020 · DOI
  117. Liu, 2019, Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control, Chem. Soc. Rev., 48, 428, 10.1039/C7CS00807D · DOI · Paper page
  118. Peulen, 2011, Diffusion of Nanoparticles in a Biofilm, Environ. Sci. Technol., 45, 3367, 10.1021/es103450g · DOI · Paper page
  119. Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 · DOI · Paper page
  120. Zou, 2016, Mechanisms of the Antimicrobial Activities of Graphene Materials, J. Am. Chem. Soc., 138, 2064, 10.1021/jacs.5b11411 · DOI · Paper page
  121. Elbourne, 2019, Multi-directional electrodeposited gold nanospikes for antibacterial surface applications, Nanoscale Adv., 1, 203, 10.1039/C8NA00124C · DOI
  122. Elahi, 2018, Recent biomedical applications of gold nanoparticles: A review, Talanta, 184, 537, 10.1016/j.talanta.2018.02.088 · DOI · Paper page
  123. Nicolae-Maranciuc, A., Chicea, D., and Chicea, L.M. (2022). Ag Nanoparticles for Biomedical Applications—Synthesis and Characterization—A Review. Int. J. Mol. Sci., 23. · DOI
  124. Jamkhande, 2019, Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications, J. Drug Deliv. Sci. Technol., 53, 101174, 10.1016/j.jddst.2019.101174 · DOI · Paper page
  125. Rani, 2023, Plant-mediated synthesis of nanoparticles and their applications: A review, Mater. Res. Bull., 163, 112233, 10.1016/j.materresbull.2023.112233 · DOI · Paper page
  126. Jadoun, 2022, Synthesis of nanoparticles using microorganisms and their applications: A review, Environ. Chem. Lett., 20, 3153, 10.1007/s10311-022-01444-7 · doi:10.1007/s10311-022-01444-7
  127. Khan, 2022, Prospects of algae-based green synthesis of nanoparticles for environmental applications, Chemosphere, 293, 133571, 10.1016/j.chemosphere.2022.133571 · DOI · Paper page
  128. Kashyap, 2021, Synthesis, characterization and application of intracellular Ag/AgCl nanohybrids biosynthesized in Scenedesmus sp. as neutral lipid inducer and antibacterial agent, Environ. Res., 201, 111499, 10.1016/j.envres.2021.111499 · DOI
  129. Zheng, 2018, Antimicrobial silver nanomaterials, Coord. Chem. Rev., 357, 1, 10.1016/j.ccr.2017.11.019 · DOI · Paper page
  130. Mozafari, 2021, Antimicrobial Applications of Nanoliposome Encapsulated Silver Nanoparticles: A Potential Strategy to Overcome Bacterial Resistance, Curr. Nanosci., 17, 26, 10.2174/18756786MTA4iMTAi3 · doi:10.2174/18756786mta4imtai3
  131. Mirzajani, 2011, Antibacterial effect of silver nanoparticles on Staphylococcus aureus, Res. Microbiol., 162, 542, 10.1016/j.resmic.2011.04.009 · DOI · Paper page
  132. Ansari, 2014, Interaction of silver nanoparticles with Escherichia coli and their cell envelope biomolecules, J. Basic. Microbiol., 54, 905, 10.1002/jobm.201300457 · doi:10.1002/jobm.201300457
  133. Garavand, 2021, Incorporation of silver nanoparticles into active antimicrobial nanocomposites: Release behavior, analyzing techniques, applications and safety issues, Adv. Colloid. Interfac., 293, 102440, 10.1016/j.cis.2021.102440 · DOI
  134. Haidari, 2022, Polycationic Silver Nanoclusters Comprising Nanoreservoirs of Ag(+) Ions with High Antimicrobial and Antibiofilm Activity, ACS Appl. Mater. Interfaces, 14, 390, 10.1021/acsami.1c21657 · DOI
  135. Wang, 2019, Anti-Biofilm Activity of Graphene Quantum Dots via Self-Assembly with Bacterial Amyloid Proteins, ACS Nano, 13, 4278, 10.1021/acsnano.8b09403 · DOI
  136. Ma, 2021, Structural mechanism for modulation of functional amyloid and biofilm formation by Staphylococcal Bap protein switch, EMBO J., 40, e107500, 10.15252/embj.2020107500 · DOI
  137. Nicastro, 2019, Bacterial Amyloids: The Link between Bacterial Infections and Autoimmunity, Trends Microbiol., 27, 954, 10.1016/j.tim.2019.07.002 · DOI
  138. Dizaj, 2014, Antimicrobial activity of the metals and metal oxide nanoparticles, Mater. Sci. Eng. C Mater. Biol. Appl., 44, 278, 10.1016/j.msec.2014.08.031 · DOI · Paper page
  139. Cui, 2012, The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli, Biomaterials, 33, 2327, 10.1016/j.biomaterials.2011.11.057 · DOI · Paper page
  140. Zhang, 2020, A glycoconjugate-based gold nanoparticle approach for the targeted treatment of Pseudomonas aeruginosa biofilms, Nanoscale, 12, 23234, 10.1039/D0NR05365A · doi:10.1039/d0nr05365a
  141. Wang, 2019, Construction of nanomaterials with targeting phototherapy properties to inhibit resistant bacteria and biofilm infections, Chem. Eng. J., 358, 74, 10.1016/j.cej.2018.10.002 · DOI · Paper page
  142. Cui, 2020, Self-Propelled Active Photothermal Nanoswimmer for Deep-Layered Elimination of Biofilm In Vivo, Nano Lett., 20, 7350, 10.1021/acs.nanolett.0c02767 · DOI · Paper page
  143. 2015, Antibacterial and Antibiofilm Activities of the Photothermal Therapy Using Gold Nanorods against Seven Different Bacterial Strains, J. Nanomater., 2015, 783671, 10.1155/2015/783671 · DOI
  144. Khantamat, 2015, Gold Nanoshell-Decorated Silicone Surfaces for the Near-Infrared (NIR) Photothermal Destruction of the Pathogenic Bacterium E. faecalis, Acs Appl. Mater. Interfaces, 7, 3981, 10.1021/am506516r · DOI
  145. Jo, 2013, Influence of the photothermal effect of a gold nanorod cluster on biofilm disinfection, Nanotechnology, 24, 195104, 10.1088/0957-4484/24/19/195104 · DOI
  146. Dong, 2022, Intelligent peptide-nanorods against drug-resistant bacterial infection and promote wound healing by mild-temperature photothermal therapy, Chem. Eng. J., 432, 134061, 10.1016/j.cej.2021.134061 · DOI
  147. Fang, 2022, Near-infrared-activated nanohybrid coating with black phosphorus/zinc oxide for efficient biofilm eradication against implant-associated infections, Chem. Eng. J., 435, 134935, 10.1016/j.cej.2022.134935 · DOI
  148. Zhuang, 2021, Bifunctional cupric oxide nanoparticle-catalyzed self-cascade oxidation reactions of ascorbic acid for bacterial killing and wound disinfection, Compos. Part B Eng., 222, 109074, 10.1016/j.compositesb.2021.109074 · doi:10.1016/j.compositesb.2021.109074
  149. Mao, 2022, Iron oxide nanoparticles for biomedical applications: An updated patent review (2015–2021), Expert. Opin. Ther. Pat., 32, 939, 10.1080/13543776.2022.2109413 · DOI
  150. Armijo, L.M., Wawrzyniec, S.J., Kopciuch, M., Brandt, Y.I., Rivera, A.C., Withers, N.J., Cook, N.C., Huber, D.L., Monson, T.C., and Smyth, H.D.C. (2020). Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms. J. Nanobiotechnol., 18. · DOI · Paper page
  151. Somanathan, 2019, Silver nanoparticles: Electron transfer, reactive oxygen species, oxidative stress, beneficial and toxicological effects. Mini review, J. Appl. Toxicol., 39, 16, 10.1002/jat.3654 · DOI · Paper page
  152. Mann, R., Holmes, A., McNeilly, O., Cavaliere, R., Sotiriou, G.A., Rice, S.A., and Gunawan, C. (2021). Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: Adaptation phenomena and cross-resistance. J. Nanobiotechnol., 19. · DOI · Paper page
  153. Musielak, E., Feliczak-Guzik, A., and Nowak, I. (2022). Synthesis and Potential Applications of Lipid Nanoparticles in Medicine. Materials, 15. · DOI · Paper page
  154. Baek, 2018, A programmable lipid-polymer hybrid nanoparticle system for localized, sustained antibiotic delivery to Gram-positive and Gram-negative bacterial biofilms, Nanoscale Horiz., 3, 305, 10.1039/C7NH00167C · DOI
  155. Wan, 2018, Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms, ACS Appl. Mater. Interfaces, 10, 10678, 10.1021/acsami.7b19762 · DOI
  156. Ma, 2017, Application, mode of action, and in vivo activity of chitosan and its micro and nanoparticles as antimicrobial agents: A review, Carbohyd. Polym., 176, 257, 10.1016/j.carbpol.2017.08.082 · DOI · Paper page
  157. Jha, R., and Mayanovic, R.A. (2023). A Review of the Preparation, Characterization, and Applications of Chitosan Nanoparticles in Nanomedicine. Nanomaterials, 13. · DOI · Paper page
  158. Ma, 2020, Preparation and antibiofilm studies of curcumin loaded chitosan nanoparticles against polymicrobial biofilms of Candida albicans and Staphylococcus aureus, Carbohydr. Polym., 241, 116254, 10.1016/j.carbpol.2020.116254 · DOI
  159. Marangon, 2020, Combination of Rhamnolipid and Chitosan in Nanoparticles Boosts Their Antimicrobial Efficacy, Acs Appl. Mater. Interfaces, 12, 5488, 10.1021/acsami.9b19253 · DOI · Paper page
  160. Varshosaz, 2012, Dextran conjugates in drug delivery, Expert Opin. Drug Deliv., 9, 509, 10.1517/17425247.2012.673580 · DOI · Paper page
  161. Naha, 2019, Dextran-Coated Iron Oxide Nanoparticles as Biomimetic Catalysts for Localized and pH-Activated Biofilm Disruption, ACS Nano, 13, 4960, 10.1021/acsnano.8b08702 · DOI · Paper page
  162. Hu, 2021, Recent advances in dextran-based drug delivery systems: From fabrication strategies to applications, Carbohydr. Polym., 264, 117999, 10.1016/j.carbpol.2021.117999 · DOI · Paper page
  163. Barros, C.H.N., Hiebner, D.W., Fulaz, S., Vitale, S., Quinn, L., and Casey, E. (2021). Synthesis and self-assembly of curcumin-modified amphiphilic polymeric micelles with antibacterial activity. J. Nanobiotechnol., 19. · DOI
  164. Li, 2022, Destructing biofilms by cationic dextran through phase transition, Carbohydr. Polym., 279, 118778, 10.1016/j.carbpol.2021.118778 · DOI
  165. Hasannia, 2022, Synthesis of block copolymers used in polymersome fabrication: Application in drug delivery, J. Control Release, 341, 95, 10.1016/j.jconrel.2021.11.010 · DOI
  166. Konai, 2018, Recent Progress in Polymer Research to Tackle Infections and Antimicrobial Resistance, Biomacromolecules, 19, 1888, 10.1021/acs.biomac.8b00458 · DOI · Paper page
  167. Takahashi, 2016, Cationic Amphiphilic Polymers with Antimicrobial Activity for Oral Care Applications: Eradication of S. mutans Biofilm, Biomacromolecules, 18, 257, 10.1021/acs.biomac.6b01598 · DOI
  168. Zhao, 2020, Screening and Matching Amphiphilic Cationic Polymers for Efficient Antibiosis, Biomacromolecules, 21, 5269, 10.1021/acs.biomac.0c01330 · DOI
  169. Vishwakarma, 2021, Peptidomimetic Polyurethanes Inhibit Bacterial Biofilm Formation and Disrupt Surface Established Biofilms, J. Am. Chem. Soc., 143, 9440, 10.1021/jacs.1c02324 · DOI · Paper page
  170. Fadaka, A.O., Sibuyi, N.R.S., Madiehe, A.M., and Meyer, M. (2021). Nanotechnology-Based Delivery Systems for Antimicrobial Peptides. Pharmaceutics, 13. · DOI
  171. Hiemstra, 2016, Antimicrobial Peptides and Innate Lung Defenses: Role in Infectious and Noninfectious Lung Diseases and Therapeutic Applications, Chest, 149, 545, 10.1378/chest.15-1353 · DOI
  172. Travkova, 2017, The interaction of antimicrobial peptides with membranes, Adv. Colloid. Interface Sci., 247, 521, 10.1016/j.cis.2017.06.001 · DOI · Paper page
  173. Wang, 2022, Advances in the development of antimicrobial peptides and proteins for inhaled therapy, Adv. Drug Deliv. Rev., 180, 114066, 10.1016/j.addr.2021.114066 · DOI
  174. Nordstrom, 2017, Delivery systems for antimicrobial peptides, Adv. Colloid. Interface Sci., 242, 17, 10.1016/j.cis.2017.01.005 · DOI · Paper page
  175. Wang, 2021, Antimicrobial peptides towards clinical application: Delivery and formulation, Adv. Drug Deliv. Rev., 175, 113818, 10.1016/j.addr.2021.05.028 · DOI · Paper page
  176. Casciaro, 2019, Poly(lactide- co-glycolide) Nanoparticles for Prolonged Therapeutic Efficacy of Esculentin-1a-Derived Antimicrobial Peptides against Pseudomonas aeruginosa Lung Infection: In Vitro and in Vivo Studies, Biomacromolecules, 20, 1876, 10.1021/acs.biomac.8b01829 · DOI
  177. Falciani, 2020, Antimicrobial Peptide-Loaded Nanoparticles as Inhalation Therapy for Pseudomonas aeruginosa Infections, Int. J. Nanomed., 15, 1117, 10.2147/IJN.S218966 · doi:10.2147/ijn.s218966
  178. Yu, 2020, Demolishing the great wall of biofilms in Gram-negative bacteria: To disrupt or disperse?, Med. Res. Rev., 40, 1103, 10.1002/med.21647 · DOI
  179. Rivero Berti, I., Islan, G.A., and Castro, G.R. (2021). Enzymes and biopolymers. The opportunity for the smart design of molecular delivery systems. Bioresour. Technol., 322. · DOI
  180. Conte, 2014, Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies, Adv. Drug Deliv. Rev., 75, 92, 10.1016/j.addr.2014.05.008 · DOI
  181. Tan, 2018, Enhancing antibiofilm activity with functional chitosan nanoparticles targeting biofilm cells and biofilm matrix, Carbohydr. Polym., 200, 35, 10.1016/j.carbpol.2018.07.072 · DOI
  182. Tasia, 2020, Enhanced eradication of bacterial biofilms with DNase I-loaded silver-doped mesoporous silica nanoparticles, Nanoscale, 12, 2328, 10.1039/C9NR08467C · DOI
  183. Zhu, 2015, Alginate lyase: Review of major sources and classification, properties, structure-function analysis and applications, Bioengineered, 6, 125, 10.1080/21655979.2015.1030543 · DOI · Paper page
  184. Daboor, 2021, Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics, J. Cyst. Fibros., 20, 264, 10.1016/j.jcf.2020.04.006 · doi:10.1016/j.jcf.2020.04.006
  185. Baker, 2016, Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms, Sci. Adv., 2, e1501632, 10.1126/sciadv.1501632 · DOI · Paper page
  186. Thorn, 2021, Protective Liquid Crystal Nanoparticles for Targeted Delivery of PslG: A Biofilm Dispersing Enzyme, ACS Infect. Dis., 7, 2102, 10.1021/acsinfecdis.1c00014 · DOI
  187. Mukherjee, 2019, Bacterial quorum sensing in complex and dynamically changing environments, Nat. Rev. Microbiol., 17, 371, 10.1038/s41579-019-0186-5 · DOI · Paper page
  188. Carradori, 2020, Biofilm and Quorum Sensing inhibitors: The road so far, Expert Opin. Ther. Pat., 30, 917, 10.1080/13543776.2020.1830059 · DOI
  189. Duplantier, M., Lohou, E., and Sonnet, P. (2021). Quorum Sensing Inhibitors to Quench P. aeruginosa Pathogenicity. Pharmaceuticals, 14. · DOI
  190. Zhao, X., Yu, Z., and Ding, T. (2020). Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria. Microorganisms, 8. · DOI · Paper page
  191. Defoirdt, 2018, Quorum-Sensing Systems as Targets for Antivirulence Therapy, Trends Microbiol., 26, 313, 10.1016/j.tim.2017.10.005 · DOI · Paper page
  192. Welsh, 2015, Small molecule disruption of quorum sensing cross-regulation in Pseudomonas aeruginosa causes major and unexpected alterations to virulence phenotypes, J. Am. Chem. Soc., 137, 1510, 10.1021/ja5110798 · DOI · Paper page
  193. Welsh, 2016, Chemical probes of quorum sensing: From compound development to biological discovery, FEMS Microbiol. Rev., 40, 774, 10.1093/femsre/fuw009 · DOI · Paper page
  194. Schutz, 2018, Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers, Beilstein J. Org. Chem., 14, 2627, 10.3762/bjoc.14.241 · DOI
  195. Ho, 2020, Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of P. aeruginosa Biofilm Infections, Angew. Chem. Int. Ed. Engl., 59, 10292, 10.1002/anie.202001407 · doi:10.1002/anie.202001407
  196. Jenal, 2017, Cyclic di-GMP: Second messenger extraordinaire, Nat. Rev. Microbiol., 15, 271, 10.1038/nrmicro.2016.190 · DOI · Paper page
  197. Hengge, 2009, Principles of c-di-GMP signalling in bacteria, Nat. Rev. Microbiol., 7, 263, 10.1038/nrmicro2109 · DOI · Paper page
  198. Cai, 2021, NO donors and NO delivery methods for controlling biofilms in chronic lung infections, Appl. Microbiol. Biotechnol., 105, 3931, 10.1007/s00253-021-11274-2 · DOI · Paper page
  199. Bartley, 2020, High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans, Case Rep. Pediat, 2020, 1536714
  200. Miller, 2012, A phase I clinical study of inhaled nitric oxide in healthy adults, J. Cyst. Fibros., 11, 324, 10.1016/j.jcf.2012.01.003 · DOI

200 of 252 shown

Cited by

See all 67

Metadata

Authors
Guo, Y., Mao, Z., Ran, F., Sun, J., Zhang, J., Chai, G., & Wang, J.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2023-11-03
Volume
15
Issue
11
Pages
2582
ISSN
1999-4923
Cited by
67
References
4
Language
en
Funders
  • Open Project of State Key Laboratory of Respiratory Disease (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
  • Guangdong Basic and Applied Basic Research Foundation (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
  • Medical Scientific Research Foundation of Guangdong Province (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
  • Fundamental Research Funds for the Central Universities (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))
  • Open Project of The Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province (SKLRD-OP-202302, 2023A1515011064, A2023090, 22qntd4503, 2019E10020 (KFJJ-202202))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. https://app.cochat.ai/papers/10.3390/pharmaceutics15112582
The paper
Guo, Y., Mao, Z., Ran, F., Sun, J., Zhang, J., Chai, G., & Wang, J. (2023). Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15112582

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.